Project Report

A Review on

HCV-induced hepatocellular carcinoma and Its management strategies

A project presented for the partial fulfillment of the requirements for the degree of Bachelor of Pharmacy

Submitted to

Department of Pharmacy

Faculty of Allied Health Sciences

Daffodil international university

Submitted by

Student Id: 183-29-142

Batch 20th DSC

Department of pharmacy

Daffodil international university

Submission Date: 22 November 2022

APPROVAL

This project titled "A Review on HCV-induced hepatocellular carcinoma and Its management strategies'' submitted by Md. Nur Uddin Id:183-29-142, Daffodil International University's Department of Pharmacy has been acknowledged as satisfactory for partial fulfillment of the criteria for the degree of Bachelor of pharmacy (B. Pharm) and its style and contents have been authorized.

BOARD OF EXAMINERS

Professor Dr. Muniruddin Ahamed

Professor & Head

Department of Pharmacy

Faculty of Allied Health Sciences

Daffodil International University

---------- Internal Examiner-1

---------- Internal Examiner-2

---------- External Examiner

CERTIFICATE

This is to certify that the result of the investigation that are embodied in this project are original and have not been submitted before in substance for any degree of this university. This entire present work submitted as a project work for the partial fulfilment of the degree of the Bachelor of Pharmacy.it based on the result of author. (Nur Uddin.ID: 183-29-142) own investigation**.**

Supervised by

Md. Mizanur Rahman

Assistant Professor

Department of Pharmacy

Faculty of Allied Health Sciences

Daffodil International University

DECLARATION

I hereby declare that, this project report is done by me under the supervision of Mr. Md. Mizanur Rahman. Assistant professor, Department of Pharmacy, Faculty of Allied Health Sciences, Daffodil International University, impartial fulfilment of the requirement for the degree of Bachelor of Pharmacy (B. Pharm). I am declaring that this project is my original work. I am also declaring that neither this project nor any part therefore has been submitted elsewhere for the award of Bachelor or any degree.

Submitted by:



Md. Nur Uddin

ID: 183-29-142

Department of Pharmacy

Faculty of Allied Health Sciences

Daffodil International University

DEDICATED

To my beloved parents, my teachers, my supervisor and my friends.

ACKNOWLEDGEMENT

I want to express my gratitude to God for providing me with the strength and vitality that I needed to finish this project.

Thank you to Daffodil International University's Department of Pharmacy in the Faculty of Allied Health Science for making the necessary resources available to me so that I could finish my project.

I would like to extend my heartfelt gratitude to Professor Dr. Muniruddin Ahamed for giving me with all the tools I required for the research. He is a professor and the head of the pharmacy department at Daffodil International University.

I would like to express my gratitude for the ongoing support to Professor Dr. Abu Naser Zafar Ullah, Dean, and the Faculty of Allied Health Sciences at Daffodil International University.

I would also like to thanks my research supervisor. Md Mizanur Rahman Assistant Professor of Pharmacy at Daffodil International University, He was kind enough to teach me what he knew and give me real, valuable advice and help. I owe her a lot, and I am very grateful to her for that.

I would like to use this occasion to convey my appreciation to each and every member of the Department's faculty for their assistance and support. I would also want to express my gratitude to my parents for the unending encouragement, support, and attention they have provided me.

Md. Nur Uddin

Author

Abstract

Hepatocellular carcinoma is the term used to describe liver cancer (HCC). Liver cancer is presently the fifth most prevalent malignancy in males and the seventh most prevalent cancer in women, with fatality rates increasing over the last 20 years. The intricacy of HCV-induced hepatocarcinogenesis is mostly due to pathway alterations that are either immune-mediated as a result of ongoing inflammation or principally driven by infectious causes. Host genetic diversity may be a risk factor for HCC according to emerging data. The initial course of therapy when a patient qualifies for a liver transplant is surgical removal or transplantation. Since it was first used to treat HCC in 2007, sorafenib has been an important part of systemic treatment that has worked well. It wasn't until 2017 that some significant strides in the creation of systemic methods were achieved. Despite this, the past several years have seen significant progress in the creation of novel treatments thanks to many clinical studies in HCC and extensive fundamental research. Recent advancements have been made in both newly developed immunotherapy methods and well-established systemic treatment approaches. The American (FDA) licensed a variety of medications between 2017 and 2020 for the treatment of HCC. These drugs include bevacizumab plus atezolizumab, regorafenib, levatinib, cabozantinib, and ramucirumab, as well as immune checkpoint antagonist like nivolumab and pembrolizumab.in this paper we review of HCV induced HCC and its therapeutic approaches.

Table of content

List Of Table

List Of FIGURE

Chapter One

Introduction

1.Introduction

Hepatocellular carcinoma (HCC) risk has been associated with a persistent hepatitis C virus (HCV) infection. [1]. The hepatitis C virus, or HCV, plays a vital role in the creation of hepatocellular carcinoma and liver damage. The Flaviviridae family of viruses includes HCV (HCC). Despite the fact that direct-acting antivirals (DAA) successfully eradicate the majority of chronic HCV infection in patients [2] around 71 million people worldwide who have HCV infection have a significant risk of getting HCC in the near future. With around 1 million deaths each year, hepatocellular carcinoma, often known as HCC, is the third-leading cause of cancer-related mortality globally. Hepatocellular carcinoma, which has an occurrence of 70% to 90%, is more likely to occur in chronic liver disease patients [3] According to research, the main causes of hepatitis in eastern Asia and sub-Saharan Africa are chronic hepatitis B virus (HBV) viruses, whereas in North America, Europe, and Japan, the major causes are hepatitis C virus (HCV) infections and intake of alcohol [4]. By combining the main risk variables from throughout the world, this was revealed. The RNA virus known as the hepatitis C virus (HCV) has a single strand that reads well. More than 9,600 nucleotide sequences are included. The translation and transcription of the RNA genome are initiated by the host cells [4]. We need to study more about HCV reproduction in order to comprehend both acute and chronic HCV infection. Connectivity, endocytosis, fusion, HCV RNA translation, proteolytic degradation, viral RNA reproduction, organization, development, and release are only a few of the many phases in the HCV cycle [5]. A variety of factors, including as persistent hepatic inflammation, liver fibrosis, hepatic steatosis, cirrhosis, irreversible epigenomic alterations, and the expansion of malignant cancer-causing cells, contribute to HCC caused by HCV over a duration of far more than two decades [6].In comparison to HBV-induced HCC, which may result from straight tumorigenesis as a consequence of the incorporation of HBV DNA into the host chromosome, the malignancy risk of HCV is thought to be indirectly connected to HCV infection, inflammation, and genetic or epigenetic changes. Numerous studies have shown that viral proteins are involved in the oxidative stress brought on by HCV infection. For the development of immunological tolerance and the progression of inflammation in hepatitis, ROS generation is essential. Fibrosis and steatosis are more likely to occur in patients with genotype 3 HCV. [7]. Chronic HCV infection, as well as the fibrosis stage, are

associated with an increased risk of HCC. HCC is rare in livers with little fibrosis, but it is very typical in cirrhotic patients (1–7% yearly). [7] Despite predictions that the development of very effective direct-acting antivirals (DAAs) for HCV would result in a decline in the occurrence of HCC linked with the virus, this has not happened. [8] HCC may still manifest in an individual even if they have a lengthy virological response (SVR). If the patient has already had extensive liver fibrosis, this is particularly true. [9]

1.1 Pathogenesis of HCC caused by HCV

Over the period of 20 to 40 years, the following set of circumstances may take place, contributing to the progression of HCC brought on by HCV. Long-lasting HCV infection, ongoing hepatic worsening, growing liver fibrosis, tumor cell cloning preceded by irreversible somatic genetic changes, and the appearance of malignant clones in a tissue milieu supportive of carcinogenesis .The following is a breakdown of these steps for your convenience, development of a chronic HCV infection There is a chance that a therapeutic approach or series of therapeutic treatments will be able to halt the progression of HCV-induced hepatic malignancies at each stage. [10] The HCV virus can only completely integrate its genetic code into the host genome since it is an RNA virus. Contrarily, HBV has the capacity to splice into the DNA of its host and unintentionally induce cancer. As a consequence, the vast majority of individuals believe that HCV's capacity to cause cancer is due to mechanisms that are not directly impacted by it. One of the main issues that has to be resolved in order to understand the pathways connecting HCV infection, aggravation, and the start of cancer is the absence of a viable in vitro model system. [11]



Figure 1: The biological causes of HCC from HCV

1.2 Interaction between the HCV and cellular pathways

The HCV virus damages the liver by releasing substances that cause myelofibrosis and swelling. These accelerators include things like oxygen-free radicals, cell damage signals, hedgehog ligands, and nucleotide s. [12] Hepatic stellate cell activation requires internal inflammatory cytokines, nuclear receptor subfamily members (such as the Farsenoid-X receptor and the Peroxisome Proliferation-Activated Receptor, among others), and transnational processes. In order to create scar tissue in the liver, stimulated hepatic stellate cells use their capacities for proliferation, contractility, fibro genesis, matrix degradation, and aggressive signaling. Hepatocytes, monocyte s, lymphocytes, and other secretory cells may get infected with HCV, which then stimulates stellate cells. TGF-beta is induced in a profibrogenic manner in the presence of HCV core and non-structural proteins [13]. HCV infection results in the manufacture of TGFB1 via the activation of many pathways, including reactive oxygen species (ROS), p38 MAPK, JNK, ERK, and NF-kappa B. [13] PDGF is the most potent signal that promotes cell proliferation. In order to do this, satellite cells are stimulated to express beta PDGF receptors as well as other cell membrane growth signaling receptors including integrins. [14] Acyclic retinoid peretinoin has been shown to be effective in preventing the formation of HCC and fibrosis in mice. The degree of hepatic fibrosis in those with persistent HCV infection is linked to a greater chance of getting HCC. These findings imply that cirrhosis-driven tumorigenesis is the primary mechanism by which HCC

associated with HCV develops. [15] Clinical data suggests that viral variables associated with HCV may influence the development of HCC and the course of the illness. For instance, genotype 3 HCV reacts poorly to DAAs, is more likely to develop steatosis, and progresses more quickly toward fibrosis. [16]. The study's findings show that interactions between HCV proteins and cellular survival and development pathways raise the risk of HCC. This demonstrates how viral proteins directly trigger the molecular actions that give rise to cancer. When the HCV protein is over expressed in mice, this causes a rise in tumor size, cellular change, and/or proliferation. [17] The virus' core protein inhibits detrimental cell cycle factors such CDKN1A, NS3, NS5A, and NS5B as well as oncogene genes like TP53, TP73, and RB1. [17] HCV core, E2, NS5A, NS5B, and NS5C all promote cellular proliferation through RAF/MAPK/ERK kinase and E2F1 pathways. The very aggressive nature of HCC tumors is a result of this. [18] The role that interferon pathway activation plays in immunity against malignancies has been clarified by recent studies. The innate immune system's reaction to HCV infection is known as interferon pathway activation. HCV's core protein prevents the NF-kappa B transcription factor from controlling immune responses. [19] While the JNK pathway, which is activated by inflammatory signals like ROS in non-parenchymal liver cells, creates an inflammatory hepatic environment that promotes the growth of HCC, viral proteins also appear to hinder innate immune system, ability to inhibit killer (nk) cells, and harm allergen cells in furthermore to trying to interfere with host immune system pathways. [20]

1.3 Molecular pathways in the development of liver cancer

Malignancies of people with HCC may vary in a variety of ways. The many stages of tumor formation are characterized by genetic alterations, reactivation or inhibition of cancer genes by cellular oncogenes, and interruption of numerous transmission networks. These connections include growth factor channels like growth factor receptors and transformation growth factor (TGF), as well as proteins like Wnt/-catenin, p53, p Rb, Ras, mitogen-activated protein kinase, phosphatidylinositol 3-kinase (PI3K)/A kt, Hedgehog, and others [21]. The capacity to identify HCC at an early stage may be significantly improved by the ability to further enrich the high-risk group via the use of diagnostic indicators of HCC risk and/or poor prognosis. Citation Only a limited number of germ line SNPs have been verified in various clinical investigations

or cohorts, despite the fact that several germ-line SNPs have been claimed to increase the risk of HCC. [22] The genetic pattern has been shown to be prognosis for liver disease process, HCC development, and continued existence in individuals with initial HCV cirrhosis, in addition to being indicative for HCC recurrence. [22]



Figure 2: major signaling pathway of HCC

1.3.1 Immune-mediated hepatic changes in HCV-induced HCC

The innate and adaptive processes may become unstable as a consequence of HCV, leading to a continuous infection. It does this in a variety of ways, including by inhibiting the production of type I interferon and encouraging CD4 T cells to develop into undesirable Th2, Th17, and T-cell activation subsets (Treg). Cytotoxic lymphocytes, CD8 T cells, and NK cells therefore struggle to fulfill their functions [23]. These modifications cause low-grade chronic liver inflammation, which keeps up the disruption of tissue homeostasis and fosters an environment that is pro-cancerous [24]. ROS and nitric oxide species are released, lipids are per-oxidized, and cytotoxic cytokines are abnormally expressed, which all contribute to this. Contrarily, this situation could make it easier for the immune system to lose track of neoplastic cells and let them evade detection, both of which may result in HCC [24]. HCC and liver cirrhosis inflammation have both been connected to the production of lymphotoxins (LT), TNF-, IL-1, IL-23, and IL-6 [25] Particularly, it seems that an optimal balance between pro-inflammatory and anti-inflammatory stimuli is necessary for HCV-induced hepatocarcinogenesis. High levels of TNF- and IL-10 have been found in the blood of people with severe liver failure and HCC [26]. In addition, it seems that IL-6

and other inflammatory cytokines only help to develop tumors when estrogen is present. Only CHC females are at a Higher risk of formation hepatocellular carcinoma, despite the fact that CHC patients have higher IL-6 levels than the general population [27]. For example, a high concentration of CD8+ T lymphocytes in cirrhotic areas but not in tumors is linked to the emergence of HCC and suggests that the disease will recur after surgery in HCV-HCC patients. In HCV patients with HCC, the number of inflammatory CD8+ cells rise. while the number of NK and NKT cells, which are known to help detect malignancy [27]

1.3.2 New blood vessel growth and spreading in HCC caused by HCV

Neoangiogenesis is necessary for malignant cells to survive, but it also makes it possible for cancer cells to spread both within and outside of the liver by enabling them to move via the new blood vessels. Because malignant cells enter the portal vein through efferent flow, HCC lesions are where cancer first spreads in the liver [28]. When epithelial cells undergo EMT, they change into mesenchymal cells, which alters the tight and adherent junction components and makes the cells migrate more swiftly and aggressively. [28] It is known that NS5A activates Twist2 to start EMT, a key transcription factor regulator of this system. The E1/E2 proteins provide a different pathway that leads to EMT. TGF- and VEGF signals are used in this pathway. HIF-1, which regulates TGF and VEGF as well as hepatoma migration and blood flow, is activated by the HCV core protein [29].

1.3.3 HCC is associated with steatohepatitis and hepatic fibrosis.

steatohepatitis is frequent in HCC brought on by HCV, inflammation and modifications to lipid metabolism may play a role in tumorigeneses [30]. The buildup of fat in the liver is a symptom of hepatic steatosis. It is widely known that HCV proteins affect the host's metabolism. This association mostly activates lipogenic pathways and decreases lipid catabolism, which may cause lipotoxicity in cancer cells [31]. ROS) are actually released as a result of endoplasmic reticulum and mitochondrial abnormalities, both of which are brought on by a buildup of free fatty acids (FFAs). As a result, oxidative stress may lead to lipid per oxidation and, when it reaches a specific threshold, trigger an inflammatory cascade that results in the production of several cytokines, including TNF and IL-1, which are intimately associated with the onset of steatohepatitis and

insulin resistance [32]. high levels of ROS encourage fibrosis by promote the production of collagen I and raising the probability of genetic variations and chromosomal instability [32] Altering the activity of hepatic T cells is one way that HCV- induced steatosis may result in HCC. The lifestyles of transgenic mice designed to continuously manufacture HCV proteins in the liver are characterized by extensive steatosis and a sustained T cell invasion dominated by CD8+ T cells that release Th2-type cytokines [33]. Recent research has shown that substantial liver infiltration and activation of CD8+ and NKT cells are necessary to produce steatosis, inflammation, and malignancy [33] in a mouse model of coupled hepatic steatosis and obesity. Additionally, obese mice have a loss of select CD4+ T lymphocytes, which lessens the immune system's capacity to combat tumors and encourages the development of HCC [34]. The mice create more lipids, mostly linoleic acid, which accounts for this. In conclusion, our data show the immune system's controversial but critical role in the development of HCC associated with HCV. They also emphasize the need for an immune-based therapeutic approach that is specifically targeted for the treatment of HCC [35]. A patient's chance of having HCC rises as their HCV infection becomes worse. the liver's fibrosis Pro-fibro genic cytokines in particular have been recognized as crucial regulators of HCC development. TGIF, a critical cytokine in the process, is required for fibro genesis to occur. Chronic stress and the activation of NF -B are not directly responsible for its production [35].

1.3.4 The significance of host and viral genetic variables in HCV - associated HCC.

Tumor formation has been linked to several gene mutations. The first gene found was the tumor-suppressor gene p53. Every time this gene is altered, either its functional status is lost or dominant-negative variations are produced [36]. We now have a better knowledge of the genetic changes that lead to HCC because of the development of whole genome sequencing, and we have discovered a set of genes that are mutated more often in HCV patients [37]. HCC risk has been linked to both host gene alterations and genetic differences in genes that stop cancer from spreading [37]. Numerous studies have been conducted using the next-generation multiple sequencing technique to learn more about the genetic variations that lead to HCV. Single nucleotide polymorphisms (SNPs) linked to HCC have recently been found through genome-wide association

studies. Several pieces of evidence connect the IFNL3/4 genes, which are members of the interferon-cytokines family, to how quickly HCV patients respond to therapies and how quickly the virus disappears on its own [38]. It has been shown that one of these changes, which is found in the 3'UTR of the IFNL3 m RNA, controls the binding of microRNAs generated as a consequence of HCV infection to the transcript. Numerous assessment investigations, especially in individuals without an SVR, have been unable to prove a connection between the harmful IFNL3 genetic variants and an elevated risk of HCC. [39] HCC has been linked to genetic variations in a number of cytokines and/or their receptors. TNF family members and new cytokines, such as the anti-inflammatory cytokines IL-10, were found. Both of these are essential to the inflammatory response that aids the body in fighting HCV. People with the TN F- GG genotype and the IL-10-deficient haplotype are more likely to formation HCC. [40]

1.4 Fibrosis and the development of HCC

Eighty to ninety percent of all instances of hepatocellular cancer are caused by cirrhotic livers. Hepatic stellate cells, commonly referred to as HSCs, become increasingly active as the liver's damage worsens. [41]. They undergo a change that makes them resemble myofibroblasts and eliminates the lipid droplets holding retinoids. Extracellular matrix synthesis, which is the initial step in the development of hepatic fibrosis, is carried out by these cells. [41] If the fibrosis worsens further, it will eventually develop into cirrhosis, which cannot be treated. Activated human stem cells (HSCs) are more susceptible to the effects of cytokines such as platelet-derived growth factor (PDGF) and fibro genic cytokines on cell proliferation (TGF-). [42] These cytokines encounter an increase during the fibro genesis process, which changes how immune cells that are invading the area transmit inflammatory signals. PDGF has the ability to activate a variety of signaling cascades, including PI3K/Akt and MAPK. In PDGF-C transgenic mice, HSCs are induced into multiplication and activation prior to the onset of fibrosis, which is then followed by the growth of HCC. Patients who undergo this procedure will eventually develop HCC. Additionally, there is a link between shrinking telomeres and liver cirrhosis. Chromosome instability and the subsequent removal of checkpoints may arise from this. [43] HCC has a number of potential causes, including cirrhosis, activated stellate cells (such as Gas 6215), increased survival factors that prevent DNA-damaged hepatocytes from dying (apoptosis), and decreased tumor surveillance

function as a result of diminished cytotoxic T cell function. [44] Stellate cells have traits that are typical of stem cells, according to recent investigations. The p75 neurotrophin receptor, nest in, CD133, and C-kit are some of these traits. The stellate cells that have been triggered seem to contribute to the niche for stem cells [44]. Hedgehog and Wnt signals, which are both crucial for stem cell differentiation and the development of cancer, are also present in stellate cells. These pieces of evidence suggest that stellate cells could be able to differentiate into growth factors and might contribute in some way to the development of HCC. [45]

1.5 Clinical stratification of the risk of HCC in HCV

Table 1: Risk factor

❖ Men sex
❖ existence of cirrhosis or severe fibrosis
❖ older demographics
❖ consequent HBV or HIV infection
❖ existence of obesity
❖ and excessive alcohol intake

Treatment approaches of HCC

- Natural compound
- Current and future medical option
- Surgical option

Chapter two

Objective of the study

2.Objective of the study

The purpose of this study is to gather the most promising data about HCV-induced HCC and treatment options for HCC. Our goal in reviewing this article is to:

- ✧ To know pathophysiology of the hepatocellular carcinoma.
- ✧ To know molecular mechanism of HCV induced HCC
- ✧ To know Role of immune-mediated liver alterations in HCV-induced HCC.
- ✧ To know Role of host and viral genetic factors in HCV-related HCC.
- ✧ Compile The therapeutic potential of natural substances for liver cancer
- ✧ Exploring the medication choice (Current and future medical option for HCC)
- ✧ Compile the under investigation medicines for HCC.
- ✧ Compile the best surgical treatment option for the HCC
- ✧ Compile it for further research determinations.

Chapter Three

Methods

3.Methods

1.1 Method of searching

The following terms were used to analyze traditional books and databases like PubMed, SciFinder, Elsevier, Springer, Scopus, Science Direct, Google Scholar, and Web of Science between 2000-2022 on Hepatocellular carcinoma is caused by HCV and has a therapeutic option for HCC.

3.2 Inclusion Criteria

- ✓ Hepatitis C virus(HCV) is a major risk factor of liver cirrhosis and hepatocellular carcinoma (HCC).
- ✓ Pathophysiology of HCV induced HCC.
- ✓ Current and future medical option for HCC.

3.3 Exclusion criteria:

- ➢ There is no Treatment able to Curable100% of HCC.
- ➢ Those drug are failed in clinical trial that are exclusion in this paper.

3.4 Data analysis:

To study and create the objects, an exploratory reading of the numerous articles was done while evaluating the work's title and abstract. After finishing the exploratory analysis, read just the papers that discussed how HCV might cause hepatocellular carcinoma and various hepatocellular carcinoma therapy options. making a primary file, working on paraphrasing, and using Grammarly before producing a final review paper.

Chapter Four

Result & Discussion

4.Result & Discussion

4.1 The therapeutic potential of natural substances for liver cancer

Piperine: Black and long peppers contain an alkaloid called Piperine that inhibits tumor growth, mutation, oxidation, and proliferation [46]. It improves the bioavailability of medicines and phytochemicals by reducing lipid per-oxidation and blocking drug-metabolizing enzymes, including aryl hydrocarbon hydrolyses and UDP glucuronyl transferase. When it interacts with the lipid milieu of the intestines, absorption is enhanced [47]. Several medications are impacted by drug resistance, some of which may be superior at treating cancer. The alkaloid also accelerated peroxide-driven, mitochondria-mediated apoptosis by boosting caspase-3 and caspase-9 activity and inhibiting catalyse. The development of HCC and receptor tyro sine kinase were inhibited by Piperine. In rats with diethylnitrosamine-induced HCC cells, Piperine promotes apoptosis. In rat hepatoma cells, Piperine decreased aflatoxin B1 toxicity and micronuclei. Mycotoxin bio activation was suppressed by cytochrome P450[48]

Turmeric: A component of turmeric known as curcumin has been shown to have many biological effects that are beneficial for treating a variety of illnesses, most notably hcc [49]. The inclusion of curcumin improved the effects of piperine on rat models of hepatocellular carcinogenesis brought on by diethylnitrosamine. In comparison to curcumin alone or a placebo, the combination caused less structural, physiological, apoptotic, and proliferative abnormalities in the rats' liver and serum [49]

Extra-virgin olive oil: Displaying a beneficial effect. Extra-virgin olive oil, which includes the phenolic substance known as oleocanthal, is the main oil source used in a balanced diet. People who consume a lot of extra-virgin olive oil have a lower risk of developing cancer, metabolic disorders, heart disease, Alzheimer's disease, and osteoporosis [50]. Oleocanthal causes apoptosis, which results in the death of cancer cells. Furthermore, ongoing inflammation increases the likelihood of fibrosis, cirrhosis, and HCC by contributing to both long-term liver damage and regeneration. This association suggests that persistent inflammation may contribute to a number of illnesses. Inflammation is often linked to HCC, which makes the liver cancer worse. When the cancer cells develop, they begin to generate more COX-2 than normal cells do [51]. Oleocanthal's anti-inflammatory properties are achieved through suppressing

COX-1 and COX-2. Ibuprofen, indomethacin, and nimesulide are examples of frequently used NSAIDs and COX inhibitors. Results revealed that oleocanthal was the most successful treatment in preventing HCC cell division among the three studied drugs. Activation of caspase-3, caspase-7, and chromatin condensation were linked to the effects of oleocanthal therapy, which included a decrease in colony development and the induction of death. An increase in the expression of H2AX, which causes an increase in the formation of reactive oxygen compounds within the cell and a depolarization of the mitochondria, is a sign of DNA damage. Oleocanthal's capacity to destroy HepG2, Huh7, and Hep3b cells while having no effect on typical human hepatocytes demonstrated its selective toxicity [52]. The G0/G1 phase of the cell cycle was stopped, and caspase and PARP cleavage increased in response to different oleocanthal doses. Oleocanthal stopped the HepG2, Huh-7, and HCClm3 HCC cells' cell cycles, preventing them from proliferating. On average, it had minimal effect on human (LO2) cells. Oleocanthal inhibited both the spread of HCC in live animals and the mobility and dispersion of HCC cells. By inhibiting STAT3 from binding to DNA and from accessing the nucleus, this herbal extract decreased the levels of the Bcl-2 family, survivin, cyclin D1, and MMP-2. Additionally, the treatment lowered p-JAK1 and p-JAK-2m, positive regulators of STAT3, and increased SHP-1, a specific STAT3 inhibitor. Twist reduction stopped the production of the transcription factor for m RNA and protein, epithelial-mesenchymal transition (EMT), which plays a role in metastasis [53].

Allium: Allium extracts have both tumor-inhibiting qualities and a decreased chance of developing cancer. Numerous flavonoid and polyphenolic substances found in these extracts inhibit carcinogenesis at different stages. Diallyl sulfide has been shown to prevent the development of tumors and hepatocyte adenomas brought on by diethylnitrosamine [54]

Cnidium officinale: Cnidium officinale Makino is only grown and harvested in China for use in traditional Chinese medicine to treat low blood pressure, menstrual irregularities, discomfort, and inflammation. These herbal extracts inhibit oral and colorectal cancer in humans as well as tumor development and spread [55]. Chang liver cells were unaffected, however HepG2 cells treated to Makino extract had a decline in cell viability and an increase in apoptotic bodies. Following exposure to the extract, the fraction of HepG2 cells in the G0/G1 phase rose and the number of cells in the S-phase

dropped, suggesting cell cycle arrest. Additionally, whereas Bcl-2, CDK4, and cyclin D expression dosages dropped, p53 and caspase-3 expression dosages rose [55].

Viscum album: The plant Viscum album var (VAV), often known as the Korean or European mistletoe, is the source of an herbal medicine used by Asian patients with chronic liver diseases. The plant's constituents promote the growth of healthy liver cells without having any negative side effects. However, at the same concentrations as the regular hepatocytes, the SK-Hep-1 cells showed anti-proliferative activity. In addition, the G0/G1 phases included much less cancer cells than the S and G2/M phases did. Additionally, the therapy led to an increase in the expression of the p21 gene and a reduction in the levels of the S-phase regulators cyclin D1 and Cdk2. Cell cycle arrest and a decline in proliferative activity were directly related to this [55].

4.2 Current and future HCC therapies

As of right now, the first line of therapy consists of Sorafenib, Lenvatinib, Bevacizumab, and Atezolizumab, while the second line consists of Regorafenib and ramucirumab. Recently, researchers have begun developing drugs that specifically target HCC. The potential for checkpoint inhibitors such Durvalumab, Camrelizumab, and Tremelimumab as therapeutics is being investigated. As potential novel treatments for HCC, tislelizumab and combined target therapy are being investigated.

4.2.1 First-line therapy

Sorafenib: Sorafenib, a multikinase blocker, inhibits the function of receptor implicated in neurogenesis and vasculature, including RAF-1, BRAF, VEGFRs, PDGFR, and KIT. [56] Sorafenib has been the standard of care for individuals with delayed HCC ever since the FDA approved it in 2007. Patients with severe HCC who were not receiving systemic therapy were included in the Sorafenib Hepatocellular Malignant Tumors Evaluation Randomly Assigned Protocol study and the Sorafenib Asia-Pacific (AP) trial. Both studies showed sorafenib to be beneficial, especially when compared to a placebo [57]. The goals were clearly positive in both trials, as shown by the sorafenib group in this research having a median survival rate (OS) that was roughly 2-3 months higher than the comparison group [57]. Secondary objectives were similarly important in both trials, and the sorafenib group outlived the control group by 2-3

months on average (OS) [57]. In contrast, neither study had a full response in the sorafenib group, and they had a relatively low partial response rate (PRR; 2% in SHARP and 3.3% in AP). The medical use of sorafenib is further constrained by the wide range of tumors, the tendency of malignancies to resist therapy, and the absence of diagnostic markers for a good response to treatment [58]. Since patients do not react to the medicine as predicted, sorafenib treatment is essential to increasing its effectiveness. Particularly important are choosing those who are most likely to respond and reducing adverse effects [58]. The largest problem is HFSR, which is also the most prevalent adverse event. Clinical supervision is required during the first two months of sorafenib therapy due to the high occurrence of HFSR [59]. Although sorafenib dose reduction and urea-based lotions are two methods to prevent or decrease the effects of HFSR, clinical monitoring is required during the first two months of sorafenib therapy. Importantly, some adverse reactions (AEs), such as those affecting the skin, may be utilized as indications to determine how effectively sorafenib will function, given the high association between bad outcomes and lifetime. The purpose of the patient selection process for the administration of sorafenib therapy is to identify the patients who are most likely to respond to the medicine. [60] examined the outcomes of two phase III clinical trials and found that sorafenib treatment improved survival in all patient groups. However, sorafenib functions better in patients with HCV, a liver-only condition (without EHS), or a lower neutrophil to lymphocyte ratio [60].

Lenvatinib: Lentitinib is a drug used as the first line of therapy for severe sickness because it inhibits VEGFR 1-3, FGFR 1-4, PDGFR, RET, and KIT [61]. Lenvatinib was shown to be equal to sorafenib in the 2018 Reflect randomized phase III study. Lenvatinib and hepatic aortic infusion chemotherapy (HAIC), which are normally used for locally advanced disease and have been demonstrated to enhance long-term survival in Japan [61], are being evaluated in a randomized controlled phase 3 study to ascertain their effectiveness and safety in patients with severe HCC. This trial (NCT03775395) seeks to compare the efficacy of combination treatment to that of HAIC alone.

Bevacizumab adjuvants atezolizumab: Immunology and more especially the ICB approach, has recently attracted a lot of attention as a potential cancer therapy and has shown excellent therapeutic success. Using ICB, one may successfully defend themselves against immunological checkpoint proteins. These proteins prevent immune

cells from functioning normally once they engage with certain ligands found in the tumor's surroundings, preventing the immune system from directly targeting the tumor [62]. One of the ligands that the immunological threshold protein PD-1 interacts with goes by the name of PD-L1. Based on the findings of the Focus on a Particular Trial (NCT03434379), which was completed in 2019, FDA approved the adjuvants bevacizumab (an anti-VEGF immunoglobulin) and atezolizumab (an anti-PD-L1 immunoglobulin) as the first-line treatments for unresectable HCC in 2020 [62]. In this phase 3 study [98], the efficacy of sorafenib was contrasted with the effectiveness of bevacizumab combined with atezolizumab. All of the HCC-positive experiment participants had never received systemic treatment previously. They numbered 501 in all. When compared to sorafenib monotherapy, the results of the combined therapy were significantly better, with the overall survival rate rising by 12.6% at 12 months and the advance survival rate significantly lengthening by 2.5 months [63]. These results led to the conclusion that the treatment of patients with a bevacizumab and atezolizumab combination was, for the most part, risk-free.

4.2.2 Second-line therapy

Regorafenib: Regorafenib was given FDA approval in April 2017 as the first medication that may be used as a second-line therapy for HCC patients whose disease grew while they were on sorafenib [64]. Regorafenib is the first medication that these patients may utilize as a second-line treatment as a result of this approval. Regorafenib, a multikinase inhibitor, targets angiogenesis factors such as VEGFR1-3, PDGFR, FGFR1, KIT, RET, and BRAF. Numerous kinases are known to be inhibited by the drug regorafenib. Regorafenib has an inhibitory effect that is much stronger than sorafenib [65]. In randomly selected, placebo-controlled phase III research conducted in 2017, regorafenib was shown to be more effective than the placebo in decreasing mortality by 37% (the median surviving time for regorafenib was 10.6 months, compared to the median survival time for the placebo) [65]. The indicator research being conducted in relation to this treatment strategy is still in its early phases.

Cabozantinib: Cabozantinib Along with primarily suppressing VEGFR2 and MET, cabozantinib also has an impact on VEGFR1/3, RET, KIT, and AXL [66]. Cabozantinib is a multitarget tyrosine kinase inhibitor (TKI). Its approval was based on

a phase III study that was randomization- and placebo-controlled and showed a 2.2-month improvement in the median life expectancy in the cabozantinib group. According to these findings, cabozantinib was more effective than sorafenib alone in extending patients' lives when taken as a second-line therapy [67]. The median life expectancy with sorafenib was 10.7 months. Furthermore, prior research has shown that cabozantinib has the ability to partially address the issue of MET-induced sorafenib resistance. Studies [67]

Ramucirumab: Ramucirumab, a recombinant IgG1 monoclonal antibody (mAb), inhibits VEGFR2 activity. Ramucirumab was given to patients with advanced HCC as a second-line treatment in a randomized phase III study. When they realized they had fallen short of their goal, they were astounded [68]. They found it unexpected that, even though a high blood level of AFP (400 ng/mL) was linked to a longer life when given in combination with ramucirumab, despite the fact that an elevated degree of AFP often implies a bad prognosis, due to the positive results of this first biosynthetic route study in HCC, the FDA approved ramucirumab as a second-line treatment for hepatocellular carcinoma with an AFP level of 400 mg/mL [68].

4.2.3. Treatment with Cytotoxic Drugs

Standard cytotoxic medications did not seem to be particularly helpful for the treatment of HCC prior to loco-regional therapy. But modern cytotoxic drugs like oxaliplatin have recently shown effectiveness in the treatment of digestive tract malignancies (stomach, colorectal, and pancreatic). Several of these medications have also been given thought as possible treatments for HCC that has advanced.

4.2.3.1 Monotherapy regimens

If the patient's general health deteriorates or if they become less tolerant to systemic treatment, a regimen of this nature is advised. Doxorubicin was one of the first chemotherapy medications used for HCC and had very excellent results [69]. DEB-TACE, as was already indicated, is the real driver for its involvement. Additionally, doxorubicin and sorafenib were combined, and the results were examined. The topic that will be described here is one of the topics that will be covered in a later portion of this study: doxorubicin may now be delivered precisely where it is required because of recent technical advancements. Capecitabine is subsequently changed into 5-

fluorouracil (5-FU), a substance that inhibits gene transcription and slows the development of cancers. Its present role in the treatment plan for HCC entails immunotherapy after resection. This is based on a randomized, controlled trial that also included a placebo [70], which showed that there was a lower survival rate and a longer time to tumor growth (40 months vs. 20 months, P = 0.0046). (53.3 percent vs. 76.7 percent). Even though this result was not achieved, the capecitabine group nevertheless had a superior 5-year overall survival rate. The drug was able to demonstrate a high level of tolerance in terms of its tolerability. Titanium silicate (TS-1), a relatively new chemotherapy medication that alters the way 5-fluorouracil (5-FU) is metabolized, increases the medicine's toxicity in malignant cells. In light of its success in treating other GI cancers, a phase 3 research trial (S-CUBE) was conducted to compare its effectiveness to a placebo in treating HCC. [71]

4.2.3.2. Politherapy regimens

As was already said, new cytotoxic drugs seem to be a good treatment option for HCC. In the EACH research (phase III trial), doxorubicin alone was compared to the FOLFOX4 combination (fluorouracil, leucovorin, and oxaliplatin) as a treatment for advanced HCC that could not be surgically removed or treated locally. [72] A response rate of 22%, a disease management rate of 66%, an advancement survival time of 4.5 months, an 8.0-month latency to cancer development, and a survival duration of 4.5 months were among the noteworthy results. There are two fascinating concepts to think about. First, overall survival was correlated with the severity of cirrhosis and the result of the treatment strategy. In instance, a positive response to GEMOX led to a longer overall mortality than a negative response (19.9 mo vs. 8.5 mo). Second, 8.5% of patients were made eligible for cancer-specific therapy, which had a down-staging effect on the neoplastic. Be aware that this tactic may have some potentially negative consequences (neurotoxicity, thrombocytopenia, neutropenia, and diarrhea). Another examination of the past. When targeted therapy proved ineffective, they considered GEMOX as a potential treatment. At six months, the survival rate was discovered to be 59%, while the advancing survival rate was found to be 3.1 months. Even in this specific study, the three variables of functional ability, alpha-fetoprotein, and BCLC score at the time of diagnosis were linked to survival. As a result, further research is needed to discover how successfully this therapy approach can treat HCC, in particular in phase 3 clinical trials. Phase-2 clinical trials have started to investigate other HCC

treatments, such as the oxaliplatin-based drug XELOX, and the findings are fascinating. [73]

4.2.4 Checkpoint inhibitors

The most effective immunotherapy for HCC right now is checkpoint Blocker. As indicated and shown in, there are a number of fresh products on the market, and several ongoing clinical studies are looking into other checkpoint blockers.

Nivolumab: Nivolumab Positive outcomes for the treatment of metastatic hepatocellular carcinoma (HCC) with the anti-PD-1 antibody nivolumab were described in 2017. [74] Individuals who satisfied the inclusion criteria but whose underlying liver dysfunction was not as severe as that of other patients underwent an escalation and expansion phase. [74] After a study comprising 262 patients showed an appropriate safety history and potential effectiveness, the FDA accelerated the approval of nivolumab for the treatment of HCC patients who had taken sorafenib. [75] A small amount of Phase 2 research is comparing Nivolumab alone and in combination with Ipilimumab. Initial studies show reasonable safety and efficacy, and therapy does put off surgical removal. Nivolumab and sorafenib were compared in the Checkpoint 459 study, a randomized, double-blind, placebo-controlled trial for HCC. [75]

Pembrolizumab: Since tyrosine kinase blockers, the first-line therapy for HCC, failed or proved to be intolerable, researchers are now studying the anti-PD-1 antibody pembrolizumab as a potential second-line therapy. A single dose of pembrolizumab was administered to patients with severe liver disease who were sorafenib-resistant, sorafenib-intolerant, or who hadn't ever taken sorafenib as part of a phase II investigation. 12.9 months was the median interval survival time, and 18% of respondents supplied information. The FDA accelerated the licensing of pembrolizumab in November 2018 for HCC patients who had previously received sorafenib treatment. [75]

Tislelizumab: The innovative anti-PD-1 antibody that Bei Gene is concentrating on creating is called tislelizumab. Tislelizumab's safety was shown at an earlier stage of study when it was utilized to treat a variety of tumor cells, including HCC. An international phase III research trial comparing tislelizumab and sorafenib as first-line therapies for incurable HCC was open to patients with inoperable HCC in 2017. [76]

Camrelizumab: Participants in China who have not responded to or survived previous systemic therapy are being sought for the anti-PD-1 antibody Camrelizumab phase II/III research. [77] Phase II early data with a response rate of 13.8% and a 6-month ultimate survival rate of 74.7% were given in 2018 at a meeting of the European Society for Medical Sciences. Only two patients (0.9%) had adverse reactions that were graded "5" according to the drug's established safety profile. [77] As of yet, we are aware of no interim date for Phase III. Those with advanced HCC or biliary tract malignancies who have not responded to prior systemic therapy are being considered for the phase II research employing Camrelizumab plus the FOLFOX4 regimen (5-fluorouracil, leucovorin, and oxaliplatin). [78]

Durvalumab: Durvalumab is the only anti-PD-L1 antibody now being evaluated in HCC clinical studies. [77] To evade immune monitoring, cancer cells over-express PD-L1 and activate PD-L1/PD-1 signaling in HCC tissues. Studies have shown that inhibiting PD-L1 and DNA methyl transferase 1 (DNMT1) dramatically slowed the growth of sorafenib-resistant HCC cell lines in vitro. As a result, a unique approach to treating sorafenib-resistant HCC may now be used. [79] To assess the effectiveness of Durvalumab alone for the chemotherapy of solid tumors, a phase I/II trial was carried out. The results were encouraging, with a 10% success rate and a 13.2-month median life span for the HCC group. [80] As of this writing, no interim findings have been released from phase III research that began in 2017 and is evaluating the effectiveness of Durvalumab and Tremelimumab combination therapy as a first-line treatment for people with advanced HCC. [80]

Tremelimumab: HCC is being studied with Tremelimumab and other anti-CTLA-4 antibodies. Research has so far been conducted on Tremelimumab alone for patients with long-term hepatitis C and HCC. The trial's positive results included a half-success rate of 17.6% among the 21 patients who participated, with an average duration to progression of 6.48 months. With only very mild and temporary adverse effects, such as an increase in transaminases, the medication was typically well tolerated. For patients with non-resettable HCC, Tremelimumab is being tested in a phase I/II study

with intervention procedures such as radio frequency ablation, trans arterial chemoembolization (TACE), and cryoablation. [81]

4.2.5 Combined targeted therapy

Ipilimumab + nivolumab: In a number of recent studies, the effectiveness of combining nivolumab with the anti-CTLA-4 antibody ipilimumab has been investigated. The findings of the CheckMate040 study have only just been made public in the United States (NCT01658878). Participants in the trial were randomly assigned to one of three ipilimumab + nivolumab treatment regimens if their HCC had not responded to sorafenib therapy. The real success rate with the adjuvant was determined to be twice as high as with nivolumab alone (31% vs. 14%). The average overall survival was 18 months. [82]

4.2.6 Adoptive cell transfer (ACT)

In order to create CARs, which are chimeric antigen receptors that accurately detect and combat malignancies, T cells are given to the patient during chimeric antigen receptor (CAR) T cell therapy. It has been shown that GPC3-specific CAR-T cells exhibit anti-tumor activity and specifically target GPC3, the therapeutic epitope for HCC [83]. Currently, this approach is being tested in a clinical study (NCT02905188). Off-target harm and cancer diversity raise significant safety and effectiveness concerns. According to recent hypotheses [83], the persistence and combination method of treating HCC, which includes CAR-T cell infiltration into tumors and enhancement of their anti-HCC impact, may benefit from PD-1 disruption. Another investigation (NCT03441100). looked at the removal of the TCR genome from cancer T cell populations to evaluate the effectiveness of IMA202, which uses transgenic internally common lymphocytes to target the antigens of malignant cells. The different ways that TCRs and CARs find antigens affects both the target antigens and how the tumor gets away [84].

4.2.7. Oncolytic virus therapy

a method of treatment used to eradicate cancer This kind of therapy employs a virus that may destroy tumor cells by triggering the immune system, which then assaults malignant tissue while protecting healthy tissues from harm. The virus can either be

one that has been carefully produced or one that emerges spontaneously. Recent studies show that granulated macrophage colonial power factor and 2nd oncogenic herpes simplex type 1 could be injected into metastatic cancer lesions to stop the growth and spread of cancer. As a consequence, patients are more likely to live longer overall. The human herpes virus type 1 oncogenic virus of the second generation is the first oncolytic viral therapy authorized for use in either the US or Europe. Reolysin (pelareorep), a wild-type reovirus variation, is used to treat cancer; bladder cancer is treated with vaccine virus JX-594 (pexastimogene devacirepvec); and head and neck cancer is treated with micro-pillar colonization differentiated adenovirus CG0070. In addition, a phase II clinical study is now being conducted in Japan to examine a third oncolytic human simplex virus. It is vital to emphasize that a novel approach to treating cancer in general and HCC in particular may begin with carcinogenic viral treatments [85].

4.3 Surgical treatment

4.3.1 minimally invasive procedures

Noninvasive techniques, such as microwave ablation (MWA), trans arterial chemoembolization (TACE), focused ultrasound (HIFU), and irreversible electroporation, may be utilized for cirrhotic people with HCC who are unable to undergo surgery (IRE). The detailed response rates for nodules with a diameter of less than 3 cm when using these approaches under picture monitoring are typically around 80%. These methods have, however, been connected to certain recurrent situations. [86]

TACE: For advanced patients with BCLC-grade B liver cancer, TACE should be utilized as the first course of therapy. TACE combines cytotoxic medicines with lip iodol that are delivered locally via a catheter to target the inhibition of blood supply to HCCs, which causes hypoxia and necrosis. TACE has also been used as a temporary solution for HCC patients awaiting a liver transplant to keep them within donation requirements by delaying the progression of their cancer. TACE increases two-year survival (HR = 0.53; 95% CI: 0.32-0.89; p = 0.017). [87]

RFA: RFA made its first proposal in 1990, but the FDA did not approve it until 2001. [88] The least intrusive treatment currently used for advanced HCC is laser therapy. The RFA produces a brief electromagnetic pulse that injures the tissue thermally before

inducing an inflammatory response and necrosis. The degree of heat damage depends on the temperature reached as well as how long it is maintained there. In recent studies, RFA has been used effectively to treat a subset of patients with HCC, and the outcomes have been positive. RFA is now acknowledged as one of the primary therapies for HCC due to its capacity to produce clean surgical margins and induce full response rates in 90–100% of HCC lesions that are less than 3 cm in size. According to the European Association for the Study of Liver Problems (EASL), the European Center for Treatment and Research of Cancer, it is acknowledged as a successful treatment approach and a workable substitute for surgical resection in operable BCLC grades 0-1. The RFA has a good safety history since only minor adverse effects are observed in around 5% of patients, and they are all temporary and unidentified. [89]

Percutaneous ethanol injection therapy (PEIT): For those with HCC who are unable to have surgery and have BCLC stage 0-A, PEIT, one of the main chemical ablation treatments, may be an alternative. [90] Because of its inexpensive cost and straightforward technical usage, it is still widely utilized. Alcohol is a cytotoxic substance that causes tumor micro-vessels to become ischemic, clot, and necrotic, which kills the tumor. Due to the considerable vascularity and soft texture of HCC, alcohol may diffusely infiltrate the tumor tissue, which allows the alcohol to have its negative effects. As a consequence, the alcohol is stronger. PEIT is often used in HCC because of its tiny size. In HCC that is more than 2 cm but less than 3 cm, the incidence of necrosis drops to roughly 70%, whereas in HCC that is less than 2 cm, it may reach 90–100%. [90]

MWA: It has also been shown that HCC responds to a thermal treatment approach. The electromagnetic wave frequencies used in MWA range from 1 to 300 GHz. It may be done intraoperatively, laparoscopically, or subcutaneously. In comparison to RFA, MWA provides a number of benefits, such as a greater temperature given to the tumor location, a faster treatment time, and no chance of skin burning. Previous randomized controlled studies that compared RFA with MWA found that both were effective; however, RFA had a slightly higher rate of local tumor control than MWA and a much lower risk of sequelae. [91]

HIFU: Another noninvasive alternative for treating advanced or metastatic HCC is high-intensity focused ultrasound (HIFU), which uses mechanical power vibrations to destroy tissue in a targeted area. Prostatitis, hyperplasia, and malignant prostate cancer have all allegedly been treated with HIFU. The technique relies on ultrasonic waves to move the particles in directions parallel and perpendicular to their line of transmission. High-signal-density concentrated ultrasonic waves (100–10,000 W/cm2) quickly elevate local temperatures to at least 56 °C and higher, resulting in hepatocellular necrosis brought on by heat shock in a matter of seconds. [92]

IRE: One of the most popular applications for IRE was as an electro-chemotherapeutic technique to alter cell permeability. IRE may cause the death of live tissue because it generates very brief electric impulses that break down the barrier and cause a loss of extracellular fluid. As a result, the cellular membranes become more severely damaged, ultimately leading to cell death. Recent research has shown that IRE may be utilized to destroy tumor cells in addition to its present use in water treatment, sterilization, or pre-processing. Features close to the wounded tissues are saved because the IRE method effectively sends an electric signal to the metastatic tumor tissue without damaging the surrounding healthy tissues. [93]

4.3.2 Radiosurgery

Leksell created the idea of radiosurgery in 1987. The upper spine and brain lesions were treated with radiosurgery using an early model, now known as the Gamma Knife. It took some time until a computer-assisted technique that is reliable and precise enough to treat additional organs, such as the liver, was developed. [94] Therefore, using the Cyber Knife System makes it possible to apply conformal radiation with precision while maintaining real lesion visibility. Stereotactic radiation treatment offers the benefit of allowing radiation therapy to be administered to a tumor that has been accurately defined while preserving the surrounding healthy tissue. Additionally, Stereotactic radiation may be used after HCC treatment to stop the development of tumors while the liver is undergoing regeneration. [94] Radiosurgery is a feasible and successful treatment option. This innovative, developing treatment is most helpful for people who cannot undergo surgery and is particularly helpful for the down-staging of malignancies prior to surgical operations like liver transplants.

4.3.4 Liver Transplantation

Donating a liver is the gold standard for treating HCC since it not only removes the tumor but also deals with its underlying cause, in this case, hepatic insufficiency. [`95] Consequently, due to the stringent requirements for organ transplants in HCC patients, only a very small proportion of people are qualified to receive a liver (the Milan criteria, which also cover individuals with one malignancy less than 5 cm or up to three tumors less than 3 cm). The limited supply of organs is to blame for this. There was a 75% chance that those who met the Milan criterion would live for at least four years. Additionally, over half of patients have liver issues as a consequence of the medication, and the danger of re-infection endures even after a liver transplant. [96] A new study suggests that using des-gamma carboxyprothrombin and alpha-fetoprotein as eligibility criteria may improve the recognition of liver transplant candidates. [96]

4.3.5 surgical resection

Surgery is generally regarded as the best course of action for HCC cases in patients who do not have substantial liver fibrosis or portal hypertension. People with chronic liver disease who have extensive procedures have an increased chance of developing hepatic failure. The risk is quite high when a larger section of the liver is removed. The heightened fatality rate of surgical removal as well as issues with internal bleeding make it less likely that it would be useful. [97] Resection of HCC is also not suggested for those with severe cirrhosis. On the other hand, recent studies show that cirrhosis patients without symptoms of portal hypertension have a low mortality rate of less than 5%. [98] Due to the significant likelihood of tumor recurrence, the 5-year survival rates for HCC patients who had partial hepatectomy vary from 60% to 70%. The development of new HCC, satellite nodules, or the presence of micro-vascular expansion might all be variables in the recurrence rate. [99]

Chapter Five

Conclusion

5.Conclusion

Hepatocellular carcinoma and cirrhosis may be brought on by chronic HCV infection. Cirrhosis .it is the leading cause of HCC in people with long-term chronic HCV infection. HCC is sometimes only found after it is advanced, making therapy difficult or impossible. Older and more modern treatments were only sporadically associated with increased survival. In truth, sorafenib only marginally extended life. Preclinical and clinical research have recently focused on novel treatment objectives, drugs, and creative ways to treat disorders. This is so that a liver transplant may be performed if the HCC is discovered early enough. Systemic treatment for advanced HCC has evolved considerably in recent years. Numerous studies are currently being carried out to better understand the processes of HCC carcinogenesis and medication resistance. Systemic therapy for HCC has advanced and gained great pace since the FDA approved sorafenib in 2007. Although a variety of multikinase inhibitors have shown success in the treatment of advanced HCC, the development of ICIs has fundamentally altered the strategy for treating advanced HCC. The Focus on a Particular Study, the HIMALAYA trial for first-line atezolizumab-bevacizumab and durvalumab-tremelimumab, and the Checkmate 410 trial for second-line nivolumab-ipilimumab provide solid evidence in favor of this.

Chapter Six

Reference

6.Reference

1. Rapisarda,V., Loreto, C.,Malaguarnera, M., Ardiri, A., Proiti, M., Rigano, G., ... & Bertino, G. (2016). Hepatocellular carcinoma and the risk of occupational exposure. World journalof hepatology, 8(13), 573.

2. Polaris Observatory HCV Collaborators. (2017). Lancet Gastroenterol Hepatol.

3. Sherman,M.(2010,February).Hepatocellular carcinoma: epidemiology, surveillance, and diagnosis. In Seminars in liver disease (Vol. 30, No. 01, pp. 003-016). © Thieme Medical Publishers.

4. Petruzziello A. Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma. Open Virol J (2018) 12:26– 32.doi: 10.2174/1874357901812010026

5. D'souza, S., Lau, K. C., Coffin, C. S., & Patel, T. R. (2020). Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World Journal of Gastroenterology, 26(38), 5759.

6. Yang, J.D., & Roberts, L. R (2010). Hepatocellular carcinoma: a global view. Nature reviews Gastroenterology & hepatology, 7(8), 448-458.

7. Chung, R. T., & Baumert, T. F. (2014). Curing chronic hepatitis C—the arc of a medical triumph. N Engl J Med, 370(17), 1576-8.

8. Blanchard, E. Belouzard, S., Goueslain, L.,Wakita, T. Dubuisson, J., Wychowski, C., & Rouillé, Y. (2006). Hepatitis C virus entrydepends on clathrin-mediated endocytosis. Journal of virology, 80(14), 6964-6972.

9. van der Meer, A. J., Veldt, B. J., Feld, J. J., Wedemeyer, H., Dufour, J. F., Lammert, F., ... & Janssen, H. L. (2012). Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. Jama, 308(24), 2584-2593.

10. Hoshida, Y., Fuchs, B. C., Bardeesy, N., Baumert, T. F., & Chung, R. T. (2014). Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. Journal of hepatology, 61(1), S79-S90.

11. Mailly, L., Robinet, E., Meuleman, P., Baumert, T. F., & Zeisel, M. B. (2013). Hepatitis C virus infection and related liver disease: the quest for the best animal model. Frontiers in microbiology, 4, 213.

12. Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015). Pathobiology of liver fibrosis: a translational success story. Gut, 64(5), 830-841.

13. Bataller, R., Paik, Y. H., Lindquist, J. N., Lemasters, J.J., & Brenner, D. A. (2004). Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology, 126(2), 529-540.

14. Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD, McCarty JH, et al. Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat Med 2013; 19:1617-1624.

15. Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004). Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology, 127(5), S35-S50.

16. Goossens, N., & Negro, F. (2014). Is genotype 3 of the hepatitis C virus the new villain? Hepatology, 59(6), 2403-2412.

17. Fukutomi, T., Zhou, Y., Kawai, S., Eguchi, H., Wands, J.R., & Li, J. (2005). Hepatitis C virus core protein stimulates hepatocyte growth: Correlation with upregulation of wnt-1 expression. Hepatology, 41(5), 1096-1105.

18. Munakata, T., Nakamura, M., Liang, Y., Li, K., & Lemon, S. M. (2005). Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. Proceedings of the National Academy of Sciences, 102(50), 18159-18164.

19. Joo, M., Hahn, Y.S., Kwon, M., Sadikot, R. T., Blackwell, T. S., & Christman, J. W. (2005). Hepatitis C virus core protein suppresses NF-κB activation and cyclooxygenase-2 expression by direct interaction with IκB kinase β. Journal of virology, 79(12), 7648-7657.

20. Li, X. D., Sun, L., Seth, R. B., Pineda, G., & Chen, Z. J. (2005). Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proceedings of the National Academy of Sciences, 102(49), 17717-17722.

21. Llovet, J.M., & Bruix, J. (2008). Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 48(4), 1312-1327.

22. Hoshida, Y., Villanueva, A., Sangiovanni, A., Sole, M., Hur, C., Anderson, K. L., ... & Golub, T. R. (2013). Prognostic gene expression signature for patients with hepatitis C–related early-stage cirrhosis. Gastroenterology, 144(5), 1024-1030.

23. Park, S.H., & Rehermann, B. (2014). Immune responses to HCV and other hepatitis viruses. Immunity, 40(1), 13-24.

24. Grivennikov, S.I., Greten, F R., & Karin, M. (2010). Immunity, inflammation, and cancer. Cell, 140(6), 883-899.

25. Nakagawa, H., Maeda, S., Yoshida, H., Tateishi, R., Masuzaki, R., Ohki, T., ... & Omata, M. (2009). Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. International journal of cancer, 125(10), 2264-2269.

26. Haybaeck,J.Zeller,N.,Wolf,M.J.,Weber,A.,Wagner,U.,Kurrer,M.O.,&Heikenwalder, M. (2009). A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer cell, 16(4), 295-308.

27. Ramzan, M., Sturm, N., Decaens, T., Bioulac-Sage, P., Bancel, B., Merle, P., ... & Leroy, V. (2016). Liver-infiltrating CD 8+ lymphocytes as prognostic factor for tumour recurrence in hepatitis C virus-related hepatocellular carcinoma. Liver International, 36(3), 434-444.

28. Nakashima, O., Sugihara, S., Kage, M., & Kojiro, M. (1995). Pathomorphologic characteristics of small hepatocellular carcinoma: a special reference to small hepatocellular carcinoma with indistinct margins. Hepatology, 22(1), 101-105.

29. Wilson,G. K.,Brimacombe,C.L.,Rowe, I.A., Reynolds, G. M., Fletcher, N. F., Stamataki, Z., ... & McKeating, J. A. (2012). A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration. Journal of hepatology, 56(4), 803-809.

30. Hwang, S. J., & Lee, S.D. (2011). Hepatic steatosis and hepatitis C: Still unhappy bedfellows. Journal of gastroenterology and hepatology, 26, 96-101.

31. Syed, G. H., Amako,Y.,& Siddiqui, A.(2010). Hepatitis C virus hijacks host lipid metabolism. Trends in Endocrinology & Metabolism, 21(1), 33-40.

32. Patel,A.,& Harrison,S.A.(2012).Hepatitis Cvirusinfection and nonalcoholic steatohepatitis. Gastroenterology & hepatology, 8(5), 305.

33. Ma, C., Kesarwala, A.H., Eggert, T., Medina-Echeverz, J., Kleiner, D. E., Jin, P., ... & Greten, T. F. (2016). NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis. Nature, 531(7593), 253-257.

34. , T. F., Duffy, A. G., & Korangy, F. (2013). Hepatocellular Carcinoma from an Immunologic PerspectiveImmunotherapy of Hepatocellular Carcinoma. Clinical Cancer Research, 19(24), 6678-6685.

35. Bressac, B., Galvin, K. M., Liang, T. J., Isselbacher, K. J., Wands, J. R., & Ozturk, M. (1990). Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proceedings of the National Academy of Sciences, 87(5), 1973-1977.

36. Tornesello, M. L., Buonaguro, L., Izzo, F., & Buonaguro, F. M. (2016). Molecular alterations in hepatocellular carcinoma associated with hepatitis B and hepatitis C infections. Oncotarget, 7(18), 25087.

37. Dragani, T. A. (2010). Risk of HCC: genetic heterogeneity and complex genetics. Journal of hepatology, 52(2), 252-257.

38. Matsuura, K., Isogawa, M., & Tanaka,Y. (2016). Host genetic variants influencing the clinical course of hepatitis B virus infection. Journal of medical virology, 88(3), 371-379.

39. Lee, M. H., Yang, H. I., Lu, S. N., Lin, Y. J., Jen, C. L., Wong, K. H., ... & Chen, C. J. (2015). Polymorphisms near the IFNL3 gene associated with HCV RNA spontaneous clearance and hepatocellular carcinoma risk. Scientific reports, 5(1), 1-12.

40. independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis C virus infection. Clin Gastroenterol Hepatol 2015; 13: 1017-1024.

41. Matsuzaki, K. (2009). Modulation of TGF-beta signaling during progression of chronic liver diseases. Frontiers in Bioscience-Landmark, 14(8), 2923-2934.

42. Parsons, C. J.,Takashima, M., & Rippe, R.A. (2007). Molecular mechanisms of hepatic fibrogenesis. Journal of gastroenterology and hepatology, 22, S79-S84.

43. Satyanarayana,A.,Manns,M.P.,&Rudolph, K.L. (2004). Telomeres and telomerase: a dual role in hepatocarcinogenesis. Hepatology, 40(2), 276-283.

44. Friedman, S. L. (2008). Mechanisms of hepatic fibrogenesis.Gastroenterology, 134(6), 1655-1669.

45. Roskams, T. (2006). Different types of liver progenitor cells and their niches. Journal of hepatology, 45(1), 1-4.

46. Tawani, A., Amanullah, A., Mishra,A.,& Kumar, A. (2016). Evidences for Piperine inhibiting cancer by targeting human G-quadruplex DNA sequences. Scientific reports, 6(1), 1-12.

47. Srinivasan, K. (2007). Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Critical reviews in food science and nutrition, 47(8), 735-748.

48. Gunasekaran, V.,Elangovan, K.,& Devaraj, S. N. (2017). Targeting hepatocellular carcinoma with piperine by radical-mediated mitochondrial pathway of apoptosis: An in vitro and in vivo study. Food and Chemical Toxicology, 105, 106-118

49. Gupta, S.C., Patchva, S., & Aggarwal,B.B.(2013).Therapeutic roles of curcumin: lessons learned from clinical trials. The AAPS journal, 15(1), 195-218.

50. Pang, K.L., & Chin, K. Y. (2018). The biological activities of oleocanthal from a molecular perspective. Nutrients, 10(5), 570.

51. Cusimano, A., Balasus, D. Azzolina, A., Augello, G., Emma, M. R., Di Sano, C., ... & Cervello, M. (2017). Oleocanthal exerts antitumor effects on human liver and colon cancer cells through ROS generation. International journal of oncology, 51(2), 533-544.

52. Pei,T.,Meng,Q.,Han,J.,Sun, H.,Li, L.,Song, R.,...& Liu, L. (2016). (−)-Oleocanthal inhibits growth and metastasis by blocking activation of STAT3 in human hepatocellular carcinoma. Oncotarget, 7(28), 43475.

53. Petrovic, V., Nepal,A., Olaisen, C., Bachke, S., Hira, J., Søgaard, C. K., ... & Otterlei, M. (2018). Anti-cancer potential of homemade fresh garlic extract is related to increased endoplasmic reticulum stress. Nutrients, 10(4), 450.

54. Sengupta, A., Ghosh, S., & Bhattacharjee, S. (2004). Allium vegetables in cancer prevention: an overview. Asian Pacific Journal of Cancer Prevention, 5(3), 237-245.

55. Hong, H., An, J. C., de La Cruz, J. F., & Hwang, S. G. (2017). Cnidium officinale Makino extract induces apoptosis through activation of caspase-3 and p53 in human liver cancer HepG2 cells. Experimental and therapeutic medicine, 14(4), 3191-3197.

56. Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., ... & Trail, P. A. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer research, 64(19), 7099-7109.

57. Qin, S., Li, A., Yi, M., Yu, S., Zhang, M., & Wu, K. (2019). Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. Journal of hematology & oncology, 12(1), 1-11.

58. Cheng, A. L., Kang, Y. K., Chen, Z., Tsao, C. J., Qin, S.,Kim, J. S., . & Guan, Z. (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. The lancet oncology, 10(1), 25-34.

59. Llovet JM, Pena CEA, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012;18(8):2290–300. https://doi.org/10.1158/1078-0432.CCR-11-2175.

60. Al-Salama, Z.T.,Syed, Y. Y.,& Scott, L. J. (2019).Lenvatinib: a review in hepatocellular carcinoma. Drugs, 79(6), 665-674.

61. Ikeda, M., Morizane,C.,Ueno, M., Okusaka, T., Ishii, H., & Furuse, J. (2018). Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Japanese journal of clinical oncology, 48(2), 103-114.

62. Greten, T. F., Lai, C.W., Li,G., & Staveley-O'Carroll, K. F. (2019). Targeted and immune-based therapies for hepatocellular carcinoma. Gastroenterology, 156(2), 510-524

63. Barson, J.R., Karatayev, O., Chang, G. Q., Johnson, D. F., Bocarsly, M. E., Hoebel, B. G., & Leibowitz, S. F. (2009). Positive relationship between dietary

fat, ethanol intake, triglycerides, and hypothalamic peptides: counteraction by lipid-lowering drugs. Alcohol, 43(6), 433-441.

64. Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., ... & Zopf, D. (2011). Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. International journal of cancer, 129(1), 245-255.

65. Carcinoma,H.(2019).Villanueva A. N Engl J Med, 380, 1450-1462.

66. Kannan, A., Wells, R. B., Sivakumar, S., Komatsu, S., Singh, K. P., Samten, B., ... & Dasgupta, S. (2016). Mitochondrial Reprogramming Regulates Breast Cancer ProgressionMitochondria in Breast Cancer. Clinical cancer research, 22(13), 3348-3360.

67. Gyawali, B., & Hwang, T. (2018). Prevalence of quality of life (QoL) outcomes and association with survival in cancer clinical trials.

68. Zhu, A.X., Park, J. O., Ryoo, B.Y.,Yen, C. J., Poon, R., Pastorelli, D., ... & Kudo, M. (2015). Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncology, 16(7), 859-870.

69. Kudo, M. (2018). Ramucirumab as second-line systemic therapy in hepatocellular carcinoma. Liver Cancer, 7(4), 305.

70. Lai, C.L., Lok, A. S. F., Wu, P. C., Chan,G.C.B., & Lin, H. J. (1988). Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer, 62(3), 479-483.

71. Xia, Y., Qiu, Y.,Li, J.,Shi, L., Wang, K., Xi, T., & Wu, M. (2010). Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial. Annals of surgical oncology, 17(12), 3137-3144.

72. Kudo, M., Moriguchi, M., Numata, K.Hidaka, H., Tanaka, H., Ikeda, M., ... & Okusaka, T. (2015). A randomized, double-blind, placebo-controlled phase III study of S-1 in patients with sorafenib-refractory advanced hepatocellular carcinoma (S-CUBE).

73. Boige,V.,Raoul, J.L., Pignon, J. P., Bouche, O., Blanc, J. F., Dahan, L.,& Ducreux, M. (2007). Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. British Journal of Cancer, 97(7), 862-867.

74. El-Khoueiry, A.B., Sangro, B., Yau, T.,Crocenzi, T. S., Kudo, M., Hsu, C., ... & Melero, I. (2017). Nivolumab in patients with advanced hepatocellular

carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. The Lancet, 389(10088), 2492-2502.

75. Okusaka, T., & Ikeda, M. (2018). Immunotherapy for hepatocellular carcinoma: current status and future perspectives. ESMO open, 3, e000455.

76. Finkelmeier, F., Waidmann, O., & Trojan, J. (2018). Nivolumab for the treatment of hepatocellular carcinoma. Expert review of anticancer therapy, 18(12), 1169-1175.

77. Okusaka, T., & Ikeda, M. (2018). Immunotherapy for hepatocellular carcinoma: current status and future perspectives. ESMO open, 3, e000455.

78. Qin, S., Chen, Z., Liu, Y., Xiong, J.,Ren, Z., Meng, Z., ... & Zou, J. (2019). A phase II study of anti–PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer.

79. Xu, F., Jin, T.,Zhu, Y.,& Dai, C. (2018). Immune checkpoint therapy in liver cancer. Journal of Experimental & Clinical Cancer Research, 37(1), 1-12.

80. Xie,Y.,Xiang,Y.,Sheng, J. Zhang, D., Yao, X., Yang, Y., & Zhang, X. (2018). Immunotherapy for hepatocellular carcinoma: current advances and future expectations. Journal of immunology research, 2018.

81. de Franchis, R. (2010). Revising consensus in portal hypertension: report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension. Journal of hepatology, 53(4), 762-768.

82. El-Khoueiry, A.B., Yau, T. Kang, Y. K., Kim, T. Y., Santoro, A., Sangro, B., ... & Hsu, C. (2021). Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.

83. June,C.H.,O'Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018). CART cell immunotherapy for human cancer. Science, 359(6382), 1361-1365.

84. Hinrichs, C. S. (2016). Molecular pathways: breaking the epithelial cancer barrier for chimeric antigen receptor and T-cell receptor gene therapy. Clinical Cancer Research, 22(7), 1559-1564.

85. Federico, S. M., McCarville, M. B., Shulkin, B. L., Sondel, P. M., Hank, J. A., Hutson, P., & Furman, W. L. (2017). A Pilot Trial of Humanized Anti-GD2 Monoclonal Antibody (hu14. 18K322A) with Chemotherapy and Natural Killer Cells in Children with Recurrent/Refractory NeuroblastomaHu14. 18K322A with Chemotherapy and NK Cells in Neuroblastoma. Clinical Cancer Research, 23(21), 6441-6449.

86. Llovet, J. M. (2005). Updated treatment approach to hepatocellular carcinoma. Journal of gastroenterology, 40(3), 225-235.

87. Ye, S. L., & Chen, R. X. (2011). Comments on management of hepatocellular carcinoma: an update. Zhonghua gan zang bing za zhi= Zhonghua ganzangbing zazhi= Chinese journal of hepatology, 19(4), 251-253.

88. Mulier, S., Ruers, T., Jamart, J., Michel, L., Marchal, G., & Ni, Y. (2008). Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial. Digestive Surgery, 25(6), 445-460.

89. uropean Association for The Study of the Liver. (2012). European Organisation for Research and Treatment of Cancer: European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol, 56, 908-943.

90. Gaiani, S., Celli, N., Cecilioni, L., Piscaglia, F., & Bolondi, L. (2003). Percutaneous treatment of hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics, 17, 103-110.

91. Shibata, T., Iimuro, Y., Yamamoto, Y., Maetani, Y., Ametani, F., Itoh, K., & Konishi, J. (2002). Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology, 223(2), 331-337.

92. Ter Haar, G., Rivens, I.,Chen, L., & Riddler, S.(1991). High intensity focused ultrasound for the treatment of rat tumours. Physics in Medicine & Biology, 36(11), 1495.

93. Davalos, R.V., Mir,L. M., & Rubinsky, B. (2005). Tissue ablation with irreversible electroporation. Annals of biomedical engineering, 33(2), 223-231.

94. Leksell, L., Lindquist, C., Adler,J. R., Leksell, D., Jernberg, B., & Steiner, L. (1987). A new fixation device for the Leksell stereotaxic system. Journal of neurosurgery, 66(4), 626-629.

95. Shi, J.H., & Line P.D. (2014). Effect of liver regeneration on malignant hepatic tumors. World Journal of Gastroenterology: WJG, 20(43), 16167.

96. Wörns,M.A.,& Galle,P.R. (2010). Future perspectives in hepatocellular carcinoma. Digestive and Liver Disease, 42, S302-S309.

97. Chan,S C.,& Fan, S.T.(2013).Selection of patients of hepatocellular carcinoma beyond the Milan criteria for liver transplantation. Hepatobiliary surgery and nutrition, 2(2), 84.

98. Llovet, J.M.,Schwartz, M., & Mazzaferro,V.(2005, May). Resection and liver transplantation for hepatocellular carcinoma. In Seminars in liver disease (Vol.

25, No. 02, pp. 181-200). Copyright© 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

99. Woerns, M.A., Weinmann, A. Schuchmann, M., &Galle,P.R.(2009).Systemic therapies in hepatocellular carcinoma. Digestive diseases, 27

100. Ikeda, M., Fujiyama, S., Tanaka, M., Sata, M., Ide, T., Yatsuhashi, H., & Watanabe, H. (2005). Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. *Journal of gastroenterology*, *40*(2), 148-156.

101. Goossens, N., & Hoshida, Y. (2015). Hepatitis C virus-induced hepatocellular carcinoma. *Clinical and molecular hepatology*, *21*(2), 105.

102. Dimri, M., & Satyanarayana, A. (2020). Molecular signaling pathways and therapeutic targets in hepatocellular carcinoma. *Cancers*, *12*(2), 491.